A study to test mirvetuximab soravtansine (IMGN853) aganist doctor's choice of cancer medicines in adults with epithelial ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer Un estudio para probar irvetuximab soravtansina (IMGN853) frente a los medicamentos que elija el médico en pacientes con cáncer epitelial de ovario, cáncer peritoneal primario o cáncer de las trompas de Falopio Stage 1: -To determine the safety and anti-tumor activity of IMGN853 administered every 3 weeks and every 4 weeks -To select the schedule of IMGN853 to continue in Stage 2 Stage 2: -To compare the o...

• Country None
• organs None
• Specialty None

A clinical study to explore the efficacy and tolerability of IMGN529 taken together with Rituximab in patients with diffuse large B-cell lymphoma (DLBCL) or other forms of non-Hodgkin's lymphoma (NHL) who have stopped responding or have failed to respond to current cancer treatments - Characterize the safety and tolerability of IMGN529 in combination with rituximab when administered IV every three weeks to adult patients with relapsed and/or refractory NHL - Determine the anti-t...

• Country None
• organs None
• Specialty None

Étude IMGN632 : étude de phase 1 randomisée évaluant la sécurité et l’efficacité de l’IMGN632 chez des patients ayant une leucémie aiguë myéloïde CD123-positive ou d’autres hémopathies malignes CD123-positives récidivantes ou réfractaires. Les hémopathies malignes regroupent un ensemble de cancers des cellules sanguines et de leurs précurseurs. On retrouve les leucémies, les lymphomes, etc. Les cellules souches hématopoïétiques sont fab...

• Country France
• organs Leucémies aiguës, Syndromes myélodysplasiques (SMD), Sang Hématologie - Autres
• Specialty Immunothérapie - Vaccinothérapie